Promising trial results on Eisai Co. and Biogen Inc.‘s Alzheimer’s drug don’t discount the need for changes to the fast-track approval pathway the FDA is using to review the product, doctors and health policy analysts say.// w/ @MedResJourno news.bloomberglaw.com/health-law-and…

@MedResJourno “Ideally, the pathway gets drugs to patients who lack meaningful options faster,” Emily Largent told me. “But before post-approval trials are completed, we are prescribing—and paying—for drugs while uncertainty remains about clinical benefits.” news.bloomberglaw.com/health-law-and…